V2 Financial group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$286K Hold
3,300
0.13% 86
2025
Q4
$280K Hold
3,300
0.14% 80
2025
Q3
$239K Hold
3,300
0.13% 78
2025
Q2
$216K Hold
3,300
0.13% 78
2025
Q1
$233K Hold
3,300
0.15% 74
2024
Q4
$217K Hold
3,300
0.13% 78
2024
Q3
$233K Hold
3,300
0.15% 69
2024
Q2
$227K Hold
3,300
0.15% 69
2024
Q1
$224K Hold
3,300
0.15% 64
2023
Q4
$204K Buy
+3,300
New +$194K 0.14% 63
2023
Q1
Sell
-3,300
Closed -$205K 61
2022
Q4
$205K Buy
+3,300
New +$198K 0.16% 60
2022
Q3
Sell
-3,300
Closed -$211K 59
2022
Q2
$211K Hold
3,300
0.17% 56
2022
Q1
$214K Hold
3,300
0.16% 58
2021
Q4
$220K Hold
3,300
0.17% 65
2021
Q3
$201K Hold
3,300
0.17% 60
2021
Q2
$204K Buy
+3,300
New +$201K 0.17% 58

Other funds holding IHE

V2 Financial group's IHE Position: Q1 2026 in Review

V2 Financial group held its iShares US Pharmaceuticals ETF (IHE) position steady in Q1 2026 at 3,300 shares worth $286K. The position accounts for 0.13% of the portfolio, ranked #86.

V2 Financial group first reported a position in IHE in Q2 2021 and has held it in 16 quarters since. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • V2 Financial group held 3,300 shares of iShares US Pharmaceuticals ETF worth $286K as of Q1 2026.
  • V2 Financial group left its iShares US Pharmaceuticals ETF share count unchanged in Q1 2026.
  • iShares US Pharmaceuticals ETF made up 0.13% of V2 Financial group's portfolio in Q1 2026, its #86 holding.
  • V2 Financial group first reported a position in iShares US Pharmaceuticals ETF in Q2 2021 and has held it in 16 quarters since.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on V2 Financial group's 13F filing for Q1 2026, filed 4 May 2026.